Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTADGlobeNewsWire • 10/31/24
Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTADGlobeNewsWire • 10/29/24
Analyses from Cognition's Positive Phase 2 ‘SHINE' Study of CT1812 in Mild-to-Moderate Alzheimer's Disease will be Presented in a Podium Presentation at CTADGlobeNewsWire • 10/23/24
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)GlobeNewsWire • 10/22/24
Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities ConferenceGlobeNewsWire • 10/02/24
Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common DementiaGlobeNewsWire • 10/01/24
Cognition Therapeutics to Participate in Upcoming September 2024 Investor ConferencesGlobeNewsWire • 09/03/24
Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's DiseaseGlobeNewsWire • 08/22/24
Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical UpdateGlobeNewsWire • 08/08/24
Cognition Therapeutics announces positive results from trial of oral treatment for mild-to-moderate Alzheimer's diseaseMarket Watch • 07/29/24
Cognition Therapeutics' Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer's PatientsGlobeNewsWire • 07/29/24
Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer's Disease at 8:30am ET on Monday July 29, 2024GlobeNewsWire • 07/26/24
Results from Cognition Therapeutics' Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer's Disease Accepted for Presentation at AAICGlobeNewsWire • 07/02/24
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's DiseaseGlobeNewsWire • 05/21/24
Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business UpdateGlobeNewsWire • 05/07/24
Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy BodiesGlobeNewsWire • 04/29/24
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer's DiseaseGlobeNewsWire • 04/22/24
Cognition Therapeutics to Present at the Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/02/24
Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer's Disease on April 12, 2024GlobeNewsWire • 04/01/24